Roche's CellCept linked to birth defects

The FDA is warning doctors and patients that CellCept, a drug for organ transplant patients, can cause miscarriages and birth defects. Made by Roche, CellCept will get a "black box" warning that it's been linked to first-trimester pregnancy loss and ear and mouth defects in infants.

Roche cited 25 miscarriages among 77 women exposed to the drug during pregnancy between 1995 and 2007; 14 of the women had babies with birth defects. However, to put this in perspective, more than 450,000 men and women have taken the drug since its 1995 approval.

- read the Houston Chronicle article for more

Related Articles:
Aspreva, Roche put CellCept on ice. Report
Aspreva's CellCept fails late-stage superiority study. Report
Aspreva Pharmaceuticals drug fails Phase III trial. Report
CellCept wins orphan status. Report

Suggested Articles

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

Pfizer struck a deal to produce Gilead Sciences' remdesivir, which has been running short at some hard-hit U.S. hospitals.